PMTCT option b+ does not increase preterm birth risk and may prevent extreme prematurity: A retrospective cohort study in Malawi

Journal of Acquired Immune Deficiency Syndromes

Volumn 74, Issue 4, 2017, Pages 367-374

  Chagomerana, Maganizo B ^a   Miller, William C ^a,b,c   Pence, Brian W ^a   Hosseinipour, Mina C ^b,d   Hoffman, Irving F ^b,d   Flick, Robert J ^d,e   Tweya, Hannock ^d   Mumba, Soyapi ^f   Chimbwandira, Frank ^g   Powers, Kimberly A ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d KAMUZU CENTRAL HOSPITAL   (Malawi)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f BAOBAB HEALTH TRUST   (Malawi)

^g MINISTRY OF HEALTH   (Malawi)

Author keywords

antiretroviral therapy; HIV; option B; PMTCT; premature; preterm birth

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONCEPTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MALAWI; MATERNAL EXPOSURE; OBSTETRIC DELIVERY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADULT; HIV INFECTIONS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; PREVENTION AND CONTROL; TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALAWI; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84996956340     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001253     Document Type: Article

References (48)

1. March of Dimes P, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth. Geneva, Switzerland: March of Dimes P, Save the Children, WHO; 2012.
2. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: An updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151-2161.
3. McCormick MC. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med. 1985;312:82-90.
4. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
5. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet. 2012;379:2162-2172.
6. UNAIDS. How AIDS Changed Everything. Geneva, Switzerland: UNAIDS; 2015.
7. de Vincenzi I. Triple antiretroviral compared with zidovudine and singledose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): A randomised controlled trial. Lancet Infect Dis. 2011;11:171-180.
8. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: The Mitra Plus study. J Acquir Immune Defic Syndr. 2009;52:406-416.
9. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010; 362:2271-2281.
10. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
11. Miro JM, Manzardo C, Mussini C, et al. Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: A cohort analysis. PLoS One. 2011;6:e26009.
12. Hargrove JW, Humphrey JH. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS. 2010;24:F11-F14.
13. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: A review of the evidence for the Option B+ approach. Curr Opin HIV AIDS. 2013; 8:474-489.
14. Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: Time for a public health approach. Lancet. 2011;378:282-284.
15. WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO; 2010.
16. CDC. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep. 2013;62:148-151.
17. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendation for a Public Health Approach. Geneva, Switzerland: WHO; 2013.
18. van der Merwe K, Hoffman R, Black V, et al. Birth outcomes in South African women receiving highly active antiretroviral therapy: A retrospective observational study. J Int AIDS Soc. 2011;14:42.
19. Lopez M, Figueras F, Hernandez S, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: Effect of HAART. AIDS. 2012;26:37-43.
20. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206:1695-1705.
21. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?. J Infect Dis. 2006;193:1195-1201.
22. Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis. AIDS. 2007;21:607-615.
23. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870.
24. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473.
25. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009;85:82-87.
26. Darak S, Darak T, Kulkarni S, et al. Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: Experiences from a PMTCT program in western India. AIDS Patient Care and STDs. 2013;27:163-170.
27. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: A single-center cohort study. J Infect Dis. 2007;196:558-561.
28. MarazziMC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25: 1611-1618.
29. Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: A cohort study. J Infect Dis. 2016;213:1057-1064.
30. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
31. Hernan MA, Hernandez-Diaz S, Werler MM, et al. Causal knowledge as a prerequisite for confounding evaluation: An application to birth defects epidemiology. Am J Epidemiol. 2002;155:176-184.
32. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923-936.
33. Aebi-Popp K, Lapaire O, Glass TR, et al. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. J Perinat Med. 2010;38:353-358.
34. Fowler M, Qin M, Fiscus S, et al. PROMISE: Efficacy and safety of 2 strategies to prevent perinatal HIV transmission. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 2015; Seattle, Washington.
35. Moodley T, Moodley D, Sebitloane M, et al. Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy Childbirth. 2016;16:35.
36. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006;70:143-150.
37. Fiore S, Ferrazzi E, Newell ML, et al. Protease inhibitor-associated increased risk of preterm delivery is an immunological complication of therapy. J Infect Dis. 2007;195:914-916; author reply 916-917.
38. El-Shazly S, Makhseed M, Azizieh F, et al. Increased expression of proinflammatory cytokines in placentas of women undergoing spontaneous preterm delivery or premature rupture of membranes. Am J Reprod Immunol. 2004;52:45-52.
39. Prigoshin N, Tambutti M, Larriba J, et al. Cytokine gene polymorphisms in recurrent pregnancy loss of unknown cause. Am J Reprod Immunol. 2004;52:36-41.
40. Clerici M, Shearer GM. A TH1-.TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-111.
41. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575-581.
42. Bengtson AM, Chibwesha CJ, Westreich D, et al. Duration of cART before delivery and low infant birthweight among HIV-infected women in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2016;71:563-569.
43. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63-67.
44. Paredes R, Cheng I, Kuritzkes DR, et al. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010;24:45-53.
45. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis. AIDS. 2012;26:2039-2052.
46. Republic of Malawi MoH. Malawi Guidelines for Clinical Management of HIV in Children and Adults. Lilongwe, Malawi: Ministry of Health; 2014.
47. Reichman NE, Kenney GM. Prenatal care, birth outcomes and newborn hospitalization costs: Patterns among Hispanics in New Jersey. Fam Plann Perspect. 1998;30:182-187, 200.
48. Vintzileos AM, Ananth CV, Smulian JC, et al. The impact of prenatal care in the United States on preterm births in the presence and absence of antenatal high-risk conditions. Am J Obstet Gynecol. 2002;187:1254-1257.